Shattuck Labs, Inc. (STTK) recently discussed the results of its Phase I clinical trial for the DR3 blocking antibody SL-325. The findings indicate promising efficacy and safety profiles, which could pave the way for further development.
In addition to the SL-325 results, the company provided an update on its pipeline, highlighting advancements in various antibody therapies that aim to address unmet medical needs.
Shattuck Labs continues to position itself as a leader in the biotech industry, focusing on innovative solutions that leverage its proprietary technology.